Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38

Brain Research

Volumn 1011, Issue 1, 2004, Pages 58-68

  Lu, Xiao Hong ^a   Bradley, Ronald J ^a,b   Dwyer, Donard S ^a,b  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Louisiana State University Health Sciences Center at Shreveport   (United States)

Author keywords

Antipsychotic; Disorders of the nervous system; Kinase; Neuroprotection; Neuropsychiatric disorders; Trophic

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; AMYLOID BETA PROTEIN[25-35]; CHLORPROMAZINE; CLOZAPINE; FLUOXETINE; FLUPHENAZINE; GLUTAMINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROLEPTIC AGENT; OLANZAPINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; RISPERIDONE; WORTMANNIN;

ANIMAL CELL; ARTICLE; CELL STRAIN; CELL STRAIN 3T3; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HYPOPHYSIS CELL; MITOGENESIS; MOLECULAR MECHANICS; MOUSE; MYELOMA CELL; MYOBLAST; NERVE CELL; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; RAT; SERUM;

AMYLOID BETA-PROTEIN; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOTTING, WESTERN; BROMODEOXYURIDINE; CELL DIVISION; CELLS, CULTURED; CEREBRAL CORTEX; CULTURE MEDIA, SERUM-FREE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROBLASTOMA; NEURONS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDE FRAGMENTS; PERTUSSIS TOXIN; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RATS; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS;

EID: 2342638276     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2004.03.018     Document Type: Article

References (45)

1. Agarwal V., Kumar P. Olanzapine in the treatment of tardive dyskinesia. J. Clin. Psychiatry. 62:2001;298-299
2. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappellari J.C., Infante M.C., Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 156:1999;1686-1696
3. Aravagiri M., Teper Y., Marder S.R. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm. Drug Dispos. 20:1999;369-377
4. Ardizzone T.D., Bradley R.J., Freeman A.M. III, Dwyer D.S. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res. 923:2001;82-90
5. Bai O., Wei Z., Lu W., Bowen R., Keegan D., Li X.-M. Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J. Neurosci. Res. 69:2002;278-283
6. Baldessarini R.J., Centorrino F., Flood J.G., Volpicelli S.A., Huston-Lyons D., Cohen B.M. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology. 9:1993;117-124
7. Chalecka-Franaszek E., Chuang D.-M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl. Acad. Sci. U. S. A. 9:1999;8745-8750
8. Chandler L.J., Guzman N.J., Sumners C., Crews F.T. Magnesium and zinc potentiate ethanol inhibition of N-methyl-D-aspartate-stimulated nitric oxide synthase in cortical neurons. J. Pharmacol. Exp. Ther. 271:1994;67-75
9. Chen G., Rajkowska G., Du F., Seraji-Bozorgzad N., Manji H.K. Enhancement of hippocampal neurogenesis by lithium. J. Neurochem. 75:2000;1729-1734
10. 1A receptors. Psychopharmacology. 162:2002;168-177
11. Daub H., Weiss U., Wallasch C., Ullrich A. Role of transactivation of the EGF receptor in signaling by G-protein coupled receptors. Nature. 379:1996;557-560
12. Duman R.S., Nakagawa S., Malberg J. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology. 25:2001;835-844
13. Dwyer D.S., Liu Y., Bradley R.J. An ethanol-sensitive variant of the PC12 neuronal cell line: sensitivity to ethanol is associated with increased cell adhesion and decreased glucose accumulation. J. Cell. Physiol. 178:1999;93-101
14. Dwyer D.S., Pinkofsky H.B., Liu Y., Bradley R.J. Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 23:1999;69-80
15. Dwyer D.S., Bradley R.J., Kablinger A.S., Freeman A.M. III Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Ann. Clin. Psychiatry. 13:2001;103-113
16. Dwyer D.S., Lu X.-H., Bradley R.J. Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Brain Res. 971:2003;31-39
17. Dwyer D.S., Lu X.-H., Freeman A.M. III Neuronal glucose metabolism and schizophrenia: therapeutic prospects? Expert Rev. Neurotherapeutics. 3:2003;29-40
18. Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J. Psychiatr. Res. 17:1982;319-334
19. Goossens V., Grooten J., Fiers W. The oxidative metabolism of glutamine. J. Biol. Chem. 271:1996;192-196
20. Hajduch E., Litherland G.J., Hundal H.S. Protein kinase B (PKB/Akt) - a key regulator of glucose transport? FEBS Lett. 492:2001;199-203
21. Henderson D.C., Cagliero E., Gray C., Nasrallah R.A., Hayden D.L., Schoenfeld D.A., Goff D.C. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: a five-year naturalistic study. Am. J. Psychiatry. 157:2000;975-981
22. Hu Y., Qiao L., Wang S., Rong S.B., Meuillet E.J., Berggren M., Gallegos A., Powis G., Kozikowski A.P. 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3K, Akt, and cancer cell growth. J. Med. Chem. 43:2000;3045-3051
23. Kahle P.J., Maas J.W. Use of CellTiter 96 reagents in a semi-automatic assay of neuronal survival. Neural Notes. 3:1997;12-14
24. Kan O., Baldwin S., Whetton A. Apoptosis is regulated by the rate of glucose transport in an interleukin 3-dependent cell line. J. Exp. Med. 180:1994;917-923
25. Kornhuber J., Schultz A., Wiltfang J., Meineke I., Gleiter C.H., Zoechling R., Boissl K., Leblhuber F., Riederer P. Persistence of haloperidol in human brain tissue. Am. J. Psychiatry. 156:1999;885-890
26. Lawlor M.A., Alessi D.R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J. Cell. Sci. 114:2001;2903-2910
27. Lewis D.A., Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci. 25:2002;409-432
28. Lieberman J., Charles C., Sharma T., Zipursky R., Kahn R., Gur R., Tohen M., Green A.I., McEvoy J., Perkins D., Hamer R.M., Nemeroff C., Rothschild A., Kuldau J., Strakowski S., Tollefson G. Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia. Biol. Psychiatry. 53:2003;178S
29. Lu X.-H., Dwyer D.S. Neurotrophic effects of atypical antipsychotic drug olanzapine via the PI3K/Akt pathway. Abstr.-Soc. Neurosci. 2003;956.12. (Online)
30. Lu X.-H., Bradley R.J., Dwyer D.S. Antipsychotic drugs affect neuronal cell viability by modulating the glucose transporter-3 (GLUT3). FASEB J. 16:2002;A188
31. βγ subunits mediate mitogen-activated protein kinase activation by the tyrosine kinase insulin-like growth factor 1 receptor. J. Biol. Chem. 270:1995;16495-16498
32. Monji A., Utsumi H., Ueda T., Imoto T., Yoshida I., Hashioka S., Tashiro K., Tashiro N. Amyloid-β-protein (Aβ) (25-35)-associated free radical generation is strongly influenced by the aggregational state of the peptides. Life Sci. 70:2002;833-841
33. Moore G.J., Bebchuk J.M., Wilds I.B., Chen G., Menji H.K. Lithium-induced increase in human brain grey matter. Lancet. 356:2000;1241-1242
34. Morooka T., Nishida E. Requirement of p38 mitogen-activated protein kinase for neuronal differentiation in PC12 cells. J. Biol. Chem. 273:1998;24285-24288
35. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry. 59:2002;337-345
36. Olesen O.V., Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther. Drug Monit. 21:1999;87-90
37. Pang L., Sawada T., Decker S.J., Saltiel A.R. Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J. Biol. Chem. 270:1995;13585-13588
38. Renshaw P.F., Yurgelun-Todd D.A., Wei H., Charles H.C., Tohen M., Sharma T., Zipursky R.B., Kahn R., Gur R.E., Green A.I., McEvoy J.P., Perkins D.O., Hamer R., Nemeroff C.B., Rothschild A.J., Kuldau J.M., Strakowski S.M., Tollefson G.D., Lieberman J.A. Olanzapine induced reductions in frontal lobe lactate levels correlate with treatment response in first episode psychosis. Biol. Psychiatry. 53:2003;67S
39. Robertson M.D., McMullin M.M. Olanzapine concentrations in clinical serum and postmortem blood specimens - when does therapeutic become toxic? J. Forensic Sci. 45:2000;418-421
40. Thompson P.M., Vidal C., Giedd J.N., Gochman P., Blumenthal J., Nicolson R., Toga A.W., Rapoport J.L. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 98:2001;11650-11655
41. Wagle A., Jivraj S., Garlock G.L., Stapleton S.R. Insulin regulation of glucose-6-phosphate dehydrogenase gene expression is rapamycin-sensitive and requires phosphatidylinositol 3-kinase. J. Biol. Chem. 273:1998;14968-14974
42. Wakade C.G., Mahadik S.P., Waller J.L., Chiu F.-C. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J. Neurosci. Res. 69:2002;72-79
43. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry. 44:1987;660-669
44. Wirshing D.A., Spellberg B.J., Erhart S.M., Marder S.R., Wirshing W.C. Novel antipsychotics and new onset diabetes. Biol. Psychiatry. 44:1998;778-783
45. Xing J., Kornhauser J.M., Xia Z., Thiele E.A., Greenberg M.E. Nerve growth factor activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways to stimulate CREB serine133 phosphorylation. Mol. Cell. Biol. 18:1998;1946-1955